Clinical assessment of chemotherapy-induced peripheral neuropathy: a discrete choice experiment of patient preferences.

Yu, A; Street, D; Viney, R; Goodall, S; Pearce, A; Haywood, P; Haas, M; Battaglini, E; Goldstein, D; Timmins, H; Park, SB

Clinical assessment of chemotherapy-induced peripheral neuropathy: a discrete choice experiment of patient preferences.

Yu, A Street, D

Viney, R

Goodall, S

Pearce, A Haywood, P

Haas, M

Battaglini, E Goldstein, D Timmins, H Park, SB

Permalink

Publisher:: SPRINGER
Publication Type:: Journal Article
Citation:: Support Care Cancer, 2021, 29, (11), pp. 6379-6387
Issue Date:: 2021-11

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

The embargo period expires on 24 Nov 2022

Adobe PDF

Download Accepted versionAdobe PDF (751.6 kB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Yu, A
dc.contributor.author	Street, D https://orcid.org/0000-0002-4476-0656
dc.contributor.author	Viney, R https://orcid.org/0000-0002-0039-9635
dc.contributor.author	Goodall, S https://orcid.org/0000-0001-6611-6565
dc.contributor.author	Pearce, A
dc.contributor.author	Haywood, P https://orcid.org/0000-0001-5031-8648
dc.contributor.author	Haas, M https://orcid.org/0000-0002-9726-3063
dc.contributor.author	Battaglini, E
dc.contributor.author	Goldstein, D
dc.contributor.author	Timmins, H
dc.contributor.author	Park, SB
dc.date.accessioned	2022-01-21T04:17:58Z
dc.date.available	2021-04-01
dc.date.available	2022-01-21T04:17:58Z
dc.date.issued	2021-11
dc.identifier.citation	Support Care Cancer, 2021, 29, (11), pp. 6379-6387
dc.identifier.issn	0941-4355
dc.identifier.issn	1433-7339
dc.identifier.uri	http://hdl.handle.net/10453/153415
dc.description.abstract	PURPOSE: Up to 40% of cancer patients treated with neurotoxic chemotherapies experience chemotherapy-induced peripheral neuropathy (CIPN). Currently, there is no gold standard assessment tool for CIPN and there is little information in the literature on patient preferences for such assessments. This study aims to address this gap by identifying the features of a CIPN assessment tool that cancer patients value. METHODS: An online discrete choice experiment (DCE) survey of neurotoxic chemotherapy-treated patients was implemented. Respondents completed 8 choice questions each. In each choice question, they chose between two hypothetical CIPN assessment tools, each described by six attributes: impact on quality of life; level of nerve damage detected; questionnaire length; physical tests involved; impact on clinic time; impact on care. RESULTS: The survey was completed by 117 respondents who had a range of cancers of which breast cancer was the most common. Respondents favoured an assessment tool that includes a physical test and that asks about impact on quality of life. Respondents were strongly opposed to clinicians, alone, deciding how the results of a CIPN assessment might influence their care especially their chemotherapy treatment. They were concerned about small changes in their CIPN, independent of clinical relevance. Respondents were willing to add half an hour to the usual clinic time to accommodate the CIPN assessment. CONCLUSION: The findings of this DCE will assist clinicians in choosing an assessment tool for CIPN that is satisfactory to both clinician and patient.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	SPRINGER
dc.relation	http://purl.org/au-research/grants/nhmrc/GNT1080521
dc.relation.ispartof	Support Care Cancer
dc.relation.isbasedon	10.1007/s00520-021-06196-8
dc.rights	info:eu-repo/semantics/embargoedAccess
dc.rights	The final publication is available at Springer via http://dx.doi.org/ 10.1007/s00520-021-06196-8
dc.subject	11 Medical and Health Sciences, 17 Psychology and Cognitive Sciences
dc.subject.classification	Oncology & Carcinogenesis
dc.subject.mesh	Antineoplastic Agents
dc.subject.mesh	Breast Neoplasms
dc.subject.mesh	Female
dc.subject.mesh	Humans
dc.subject.mesh	Patient Preference
dc.subject.mesh	Peripheral Nervous System Diseases
dc.subject.mesh	Quality of Life
dc.subject.mesh	Humans
dc.subject.mesh	Breast Neoplasms
dc.subject.mesh	Peripheral Nervous System Diseases
dc.subject.mesh	Antineoplastic Agents
dc.subject.mesh	Quality of Life
dc.subject.mesh	Female
dc.subject.mesh	Patient Preference
dc.title	Clinical assessment of chemotherapy-induced peripheral neuropathy: a discrete choice experiment of patient preferences.
dc.type	Journal Article
utslib.citation.volume	29
utslib.location.activity	Germany
utslib.for	11 Medical and Health Sciences
utslib.for	17 Psychology and Cognitive Sciences
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Business
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Strength - CHERE - Centre for Health Economics Research and Evaluation
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Centre for Health Economics Research and Evaluation
utslib.copyright.status	open_access	*
utslib.copyright.embargo	2022-11-24T00:00:00+1000Z
dc.date.updated	2022-01-21T04:17:56Z
pubs.issue	11
pubs.publication-status	Published
pubs.volume	29
utslib.citation.issue	11

Abstract:

PURPOSE: Up to 40% of cancer patients treated with neurotoxic chemotherapies experience chemotherapy-induced peripheral neuropathy (CIPN). Currently, there is no gold standard assessment tool for CIPN and there is little information in the literature on patient preferences for such assessments. This study aims to address this gap by identifying the features of a CIPN assessment tool that cancer patients value. METHODS: An online discrete choice experiment (DCE) survey of neurotoxic chemotherapy-treated patients was implemented. Respondents completed 8 choice questions each. In each choice question, they chose between two hypothetical CIPN assessment tools, each described by six attributes: impact on quality of life; level of nerve damage detected; questionnaire length; physical tests involved; impact on clinic time; impact on care. RESULTS: The survey was completed by 117 respondents who had a range of cancers of which breast cancer was the most common. Respondents favoured an assessment tool that includes a physical test and that asks about impact on quality of life. Respondents were strongly opposed to clinicians, alone, deciding how the results of a CIPN assessment might influence their care especially their chemotherapy treatment. They were concerned about small changes in their CIPN, independent of clinical relevance. Respondents were willing to add half an hour to the usual clinic time to accommodate the CIPN assessment. CONCLUSION: The findings of this DCE will assist clinicians in choosing an assessment tool for CIPN that is satisfactory to both clinician and patient.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/153415